Table 2 Subgroup analyses of statin use and risk of endocrine-related gynecologic cancers
From: Statin use and the risk of ovarian and endometrial cancers: a meta-analysis
Characteristics | Ovarian Cancer | Endometrial Cancer | ||||||
|---|---|---|---|---|---|---|---|---|
Study number | RR(95%CI) | P value | Heterogeneity | Study number | RR(95% CI) | P value | Heterogeneity | |
Study type | 10 | 0.88 (0.76,1.03) | 0.12 | 55.0% | 16 | 0.88 (0.78,1.00) | 0.05 | 66.3% |
 RCT | 1 | 0.20 (0.01,4.07) | 0.30 | 0.0% | 2 | 0.72 (0.19,2.68) | 0.62 | 0.0% |
 Cohort | 4 | 0.98 (0.77,1.24) | 0.85 | 38.9% | 7 | 0.93 (0.80,1.10) | 0.38 | 66.5% |
 Case-control | 5 | 0.82 (0.65,1.04) | 0.10 | 70.6% | 7 | 0.80 (0.62,1.03) | 0.09 | 74.1% |
Percentage of cancer cases | ||||||||
  ≥ 1% | 4 | 0.76 (0.55,1.05) | 0.10 | 76.8% | 6 | 0.79 (0.54,1.15) | 0.21 | 76.5% |
  < 1% | 6 | 0.97 (0.83,1.14) | 0.74 | 16.6% | 10 | 0.90 (0.78,1.04) | 0.14 | 61.8% |
Study location | ||||||||
 North America | 6 | 0.88 (0.69,1.12) | 0.29 | 58.1% | 9 | 0.90 (0.73,1.11) | 0.31 | 64.2% |
 Europe | 4 | 0.90 (0.72,1.12) | 0.34 | 52.7% | 6 | 0.89 (0.75,1.05) | 0.18 | 72.2% |
 Asia | 0 | – | – | – | 1 | 0.43 (0.20,0.94) | 0.03 | 0.0% |
Quality of studies | ||||||||
 High | 9 | 0.86 (0.74,1.01) | 0.07 | 57.4% | 13 | 0.88 (0.78,1.01) | 0.06 | 68.5% |
 Low | 1 | 1.24 (0.72,2.12) | 0.44 | 0.0% | 3 | 0.80 (0.39,1.62) | 0.53 | 67.4% |
Dduration of statin use | ||||||||
 long-term use | 5 | 0.73 (0.51,1.04) | 0.08 | 58.9% | 6 | 0.79 (0.58,1.08) | 0.14 | 58.2% |
Study in diabetics | 1 | 0.96 (0.75,1.23) | 0.75 | 0.0% | 1 | 0.78 (0.65,0.94) | 0.01 | 0.0% |